Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.31 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.31 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | GPR4 | P46093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15101376 | 0.91 | PDE4B (0.39) | PDE4BPDE7AENPP2NR1H2SUV39H2 | |
| SCHEMBL10069876 | 0.90 | PDE4B (0.40) | PDE4BPDE7AENPP2NR1H2PDE3B | |
| SCHEMBL10069920 | 0.89 | PDE4B (0.40) | PDE4BPDE7AENPP2NR1H2PDE3B | |
| SCHEMBL10069923 | 0.89 | PDE4B (0.41) | PDE4BPDE7AENPP2NR1H2PDE3B | |
| SCHEMBL368710 | 0.88 | TLR9 (0.40) | PDE4BPDE7A | |
| SCHEMBL10071000 | 0.88 | PDE4B (0.41) | PDE4BPDE7AENPP2NR1H2PDE3B | |
| SCHEMBL15101649 | 0.88 | PDE4B (0.39) | PDE4BPDE7AENPP2NR1H2PDE3B | |
| SCHEMBL10070065 | 0.87 | PDE4B (0.39) | PDE4BPDE7AENPP2 | |
| SCHEMBL15101329 | 0.86 | ENPP2 (0.39) | PDE4BPDE7AENPP2 | |
| SCHEMBL10070937 | 0.85 | PDE4B (0.40) | PDE4BPDE7AENPP2NR1H2SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) | 2013-07-11 | — | — | US | disclosed |
| WO-2012006680-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | AVEXA LIMITED (AU) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178469-A1 | NOVEL ANTIVIRAL AGENTS | EIF2AK2, IFNAR1, IRF3 | PDE4B 209/4885PDE7A 200/4885ENPP2 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.